Artificial Intelligence aimed at detecting skin cancer is not yet ready for use in primary care

Published: 25th May, 2022

Artificial Intelligence (AI) aimed at detecting skin cancer earlier is not yet ready for use in primary care settings, due to a lack of evidence in settings where the prevalence of skin cancer is low, according to CanTest researchers.

Professor Serena Nik-Zainal elected a Fellow of the European Academy of Cancer Sciences 

Published: 16th May, 2022

Congratulations to Serena Nik-Zainal who has been elected a Fellow of the prestigious European Academy of Cancer Sciences, following nominations for the 2020-2021 election.

Cambridge early detection researcher announced as a Fellow of the Royal Society

Published: 10th May, 2022

Professor Douglas Easton is one of three CRUK Cambridge Centre members to be elected as a Fellow of the Royal Society in 2022. Doug is a Professor of Genetic Epidemiology at the University of Cambridge and a member of the Early Cancer Institute. Nine Cambridge scientists are among the new fellows, who are selected for their outstanding contributions to science.

£6.4 million for pioneering "sponge on a string" trial

Published: 28th April, 2022

Millions of pounds in funding has been announced for a trial that could pave the way for a ‘sponge on a string’ test to be established as a routine screening programme to detect Barrett’s oesophagus – a condition that can lead to oesophageal cancer.

Largest study of whole genome sequencing data reveals new clues to causes of cancer

Published: 21st April, 2022

In the largest study of its kind, a team of scientists led by Professor Serena Nik-Zainal has uncovered a 'treasure trove' of clues from their whole genome sequencing of human cancers that will allow them to detect patterns in the DNA of cancer, or ‘mutational signatures’, providing a personal history of the damage and repair processes each patient has been through.

Cambridge researchers outline their vision for early cancer detection

Published: 20th April, 2022

Rebecca Fitzgerald and colleagues from the University of Cambridge have written a review of the latest advances in early cancer detection. Published in Nature Medicine, their article explores who should be tested and how. They also consider future strategies that take a proactive approach to personalised, risk-based screening and offer some more radical ideas that could lead to new paradigms for early cancer detection.

The article is part of a Focus Issue in Nature Medicine, dedicated to 'The Future of Cancer Research', which takes stock of progress and explores ways to deliver research and care that is innovative, sustainable, and patient-focused.

Cambridge researchers awarded four competitive ACED grants worth over £2.1m

Published: 13th April, 2022

In a highly competitive funding round focusing on the question: Can the early detection of cancer be informed by an improved understanding of disease progression from early pre-malignant changes to consequential cancer? Cambridge researchers have successfully secured over £2million funding from Cancer Research UK's ACED Alliance.

Review article looks at the importance and challenges of early detection of cancer

Published: 21st March, 2022

Cancer early detection experts from Cambridge have contributed to a review that discusses approaches to enable early detection of cancer, allow earlier intervention and increase survival.

Published in the journal 'Science', the review highlights five challenges facing the field, current work in those areas, and where more research is needed to make early detection a reality.

Personalised blood test can detect persistent lung cancer

Published: 17th March, 2022

The results from the Lung Cancer Circulating Tumour DNA (LUCID-DNA) study, funded by Cancer Research UK, have been published today (Thursday 17th March) in the Annals of Oncology.

It details how researchers at the University of Cambridge have developed a personalised blood test to identify patients who are at higher risk of their lung cancer returning after treatment.

The personalised blood test is a type of liquid biopsy that can pick up tiny fragments of DNA that are released into the blood as tumours grow. This DNA, called circulating tumour DNA (ctDNA), can reveal the state of the tumour, its location and potentially its weaknesses, which could be used to select the best treatments.

Cambridge Early Detection researchers contribute to EU Cancer Screening reports

Published: 08th March, 2022

Researchers from the Cambridge Early Detection Programme played a key contribution to a new report by the EU Commission's Group of Chief Scientific Advisors, which provides advice and recommendations on improving cancer screening across the EU.

Page 1 of 15. 142 Items Found.